JP2012532899A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532899A5
JP2012532899A5 JP2012519900A JP2012519900A JP2012532899A5 JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5 JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5
Authority
JP
Japan
Prior art keywords
het
conr
hal
atoms
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519900A
Other languages
English (en)
Japanese (ja)
Other versions
JP5681182B2 (ja
JP2012532899A (ja
Filing date
Publication date
Priority claimed from DE102009033208A external-priority patent/DE102009033208A1/de
Application filed filed Critical
Publication of JP2012532899A publication Critical patent/JP2012532899A/ja
Publication of JP2012532899A5 publication Critical patent/JP2012532899A5/ja
Application granted granted Critical
Publication of JP5681182B2 publication Critical patent/JP5681182B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519900A 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体 Expired - Fee Related JP5681182B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009033208A DE102009033208A1 (de) 2009-07-15 2009-07-15 Aminopyridinderivate
DE102009033208.1 2009-07-15
PCT/EP2010/003659 WO2011006567A1 (de) 2009-07-15 2010-06-17 Aminopyridinderivate zur behandlung von tumoren und entzündungskrankheiten

Publications (3)

Publication Number Publication Date
JP2012532899A JP2012532899A (ja) 2012-12-20
JP2012532899A5 true JP2012532899A5 (enExample) 2013-08-29
JP5681182B2 JP5681182B2 (ja) 2015-03-04

Family

ID=42665826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519900A Expired - Fee Related JP5681182B2 (ja) 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体

Country Status (11)

Country Link
US (1) US8648201B2 (enExample)
EP (1) EP2454253B1 (enExample)
JP (1) JP5681182B2 (enExample)
CN (1) CN102471317B (enExample)
AR (1) AR077567A1 (enExample)
AU (1) AU2010272920B2 (enExample)
CA (1) CA2768169C (enExample)
DE (1) DE102009033208A1 (enExample)
ES (1) ES2534095T3 (enExample)
IL (1) IL217467A (enExample)
WO (1) WO2011006567A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574786A (zh) * 2009-04-02 2012-07-11 默克雪兰诺有限公司 二氢乳清酸脱氢酶抑制剂
CA2780031A1 (en) * 2009-11-12 2011-05-19 Selvita S.A. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP5690839B2 (ja) * 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
AU2012225805B2 (en) * 2011-03-04 2017-03-02 Lexicon Pharmaceuticals, Inc. MST1 kinase inhibitors and methods of their use
WO2013019682A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013106614A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CA2878621C (en) * 2012-07-10 2020-09-15 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
WO2014058691A1 (en) * 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2903617B1 (en) 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP3019171B1 (en) 2013-07-11 2018-09-05 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
DK3107901T3 (da) 2014-02-19 2020-06-22 Piramal Entpr Ltd Forbindelser til brug som gpr120 agonister
CA2955919A1 (en) 2014-07-25 2016-01-28 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
EP3191463B1 (en) * 2014-09-11 2019-10-30 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
TWI898556B (zh) 2018-07-13 2025-09-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
CN112457308B (zh) * 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
WO2022076975A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2023166351A1 (zh) * 2022-03-02 2023-09-07 杭州百诚医药科技股份有限公司 组胺h3受体抑制剂及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
WO2003030902A1 (en) 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
MXPA04007697A (es) * 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
EP2004625B1 (en) 2006-03-22 2009-12-30 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2009005337A1 (en) 2007-06-29 2009-01-08 Vekoma Rides Engineering B.V. Amusement device seat assembly
WO2009024825A1 (en) * 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
MX2010004491A (es) * 2007-10-25 2010-06-21 Astrazeneca Ab Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
KR100979439B1 (ko) 2008-04-10 2010-09-02 한국화학연구원 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2012532899A5 (enExample)
JP2012506389A5 (enExample)
JP2014508811A5 (enExample)
JP2011530545A5 (enExample)
JP2010529051A5 (enExample)
JP2012092103A5 (enExample)
JP2010532768A5 (enExample)
JP2014508753A5 (enExample)
JP2012111953A5 (enExample)
JP2010526025A5 (enExample)
JP2010095546A5 (enExample)
JP2009529540A5 (enExample)
JP2015536947A5 (enExample)
JP2013542218A5 (enExample)
JP2012506896A5 (enExample)
JP2009501198A5 (enExample)
JP2018533593A5 (enExample)
JP2010510177A5 (enExample)
JP2015522650A5 (enExample)
JP2013521295A5 (enExample)
JP2010513337A5 (enExample)
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JP2010536766A5 (enExample)
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
HRP20171258T1 (hr) Acilamino-supstituirani kondenzirani derivati ciklopentankarboksilne kiseline i njihova upotreba kao farmaceutski proizvodi